TPIV - Update rally with Catalyst NewsTapImmune Inc. (TPIV) has shown resilience and bounces back on another strong volume day even after close to 2 million shares exchanging hands yesterday. Our technical analysis and report on TPIV has hit the nail right on the head. Since our initial and continuous coverage on TapImmune Inc. (TPIV), the technical chart wreaks of bulls and another breakout session seems imminent in our opinion! Make sure you continue to follow the intraday moves as they seem to be very profitable!
As we said in our last report on TPIV, "The Stage is set for this Biotech Company with Catalyst News". Yesterday TPIV advances their intellectual property in the research to fight Cancer. Just yesterday the company announced very promising news in our opinion that, "the US Patent Office has issued Patent 7,994,146 entitled "Method of Enhancing an Immune Response". The invention relates to a method of enhancing an immune response to an antigen by augmenting the level of TAP (Transporters Associated with Antigen Processing) molecule in a target cell bearing the antigen. This patent details application to treating vaccinia, herpes simplex and influenza virus infections and small cell lung cancer. Levels of TAP in humans correlate with susceptibility to certain diseases and the ability to respond to a vaccine.
"The issuance of this patent reflects our strategy to continually expand and strengthen our IP portfolio and demonstrates the broad applicability of our TAP platform in multiple therapeutic areas," said Glynn Wilson Chairman and CEO of TapImmune. TapImmune's unique approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of TAP. Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers and infectious diseases.
TapImmune's lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is entering clinical co-development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer. The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases.
Next generation smallpox and tuberculosis vaccines containing TAP genes are currently in preclinical development."
Again if you visit their website you can discover that TPIV is not your overnight biotech story. It has been around for years.
Cancer, the Immune System, and TAP - In many cancers the tumor associated antigen is missing from MHC class I because the assembly of this complex has been disrupted. This occurs in many tumors because TAP is expressed at very low levels. As a consequence, tumor associated antigens generated in cancerous cells are not transported into the ER, thus preventing the assembly of functional MHC class I antigen. This results in the MHC on the cell surface missing the tumor antigen peptides that identify the cell as being cancerous. These cells, without functional MHC on their cell surface, are hidden from the cellular arm of the immune system and grow into tumors that eventually kill the person. Loss of TAP expression in tumors is highly correlated with disease progression and survival rates in humans. Clinical studies on melanoma when examining primary and metastatic tumors, show a clear and significant correlation between TAP expression and survival. Clinical studies on resected tumors correlate metastasis of breast cancer, prostate cancer, colorectal cancer, small cell lung cancer, renal cancer, squamous cell carcinoma, cervical cancer, laryngeal papillamatosis, with low or absent TAP expression.
You can continue your research to view their various product pipeline and patents here. https://www.tapimmune.com/technology/product_development/
Again put TPIV immediately on your radars as we monitor the current technicals and corporate developments for weeks!
About TapImmune Inc.- https://www.tapimmune.com:
TapImmune's unique approach is designed to increase the efficacy of vaccines by enhancing antigen presentation through the use of the Transporter of Antigen Processing ('TAP'). Replacement of this transporter provides a significant immune response with the potential to treat a variety of cancers which lack normal amounts of TAP. TapImmune's lead product candidate, AdhTAP, is designed to restore and augment antigen presentation and subsequent recognition and killing of cancer cells by the immune system. The Company is currently planning the development of AdhTAP for the commencement of clinical manufacturing and toxicology studies. As a stand-alone cancer therapy or in combination with other drugs, AdhTAP could prove to be a key component of a more successful assault on cancer. TapImmune is initiating clinical development of a multi-component vaccine for the treatment of HER-2/neu positive breast cancer.
The Company is also developing a TAP-based prophylactic vaccine which initial tests indicate may increase the efficacy of targeted prophylactic vaccines by up to 1000 times. TapImmune's TAP technology could significantly improve the efficacy of many current prophylactic vaccines and enhance the creation of new ones in the fight against many pandemic infectious diseases. A next generation smallpox vaccine is currently in preclinical development.